Table 1 Clinical data of 17 patients with PTU-induced AAV and 64 patients with primary AAV
| Â | PTU-induced AAV | Primary AAV |
|---|---|---|
(n = 17) | (n = 64) | |
Male/female | 2/15 | 32/32 |
Age (years) | 30.8 ± 15.2 | 60.48 ± 15.14 |
Scr (μM) |  |  |
Mean ± SD | 75.62 ± 40.64 | 339.11 ± 237.71 |
Range | 38-176.9 | 70-1007 |
Renal insufficiency at diagnosis | 13 (76.4%) | 48 (75%) |
ESR (mm/1 hour) | 46.92 ± 38.86 | 70.05 ± 40.14 |
Skin rash | 5(29.4%) | 7 (10.9%) |
Arthralgia | 9(52.9%) | 15(23.4%) |
Muscle pain | 6 (35.3%) | 10 (15.6%) |
Lung | 6 (35.3%) | 43 (67.2%) |
ENT | 6 (35.2%) | 27(42.2%) |
Ophthalmic | 2 (11.8%) | 14(21.9%) |
Gastrointestinal | 3(17.6%) | 11(17.2%) |
Nervous system | 1 (5.9%) | 10(15.6%) |
BVAS | Â | Â |
Mean ± SD | 17.1 ± 5.5 | 20.27 ± 5.18 |
Range | 7-31 | 13-36 |